| UHC Commercial Medical & Drug | Surgery of the Foot – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Treatment of Temporomandibular Joint Disorders – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Whole Exome and Whole Genome Sequencing (Non-Oncology Conditions) – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC Surest Medical and Drug | FcRn Blockers – Commercial Medical Benefit Drug Policy | 2026-10-01 |
| UHC Surest Medical and Drug | Tzield® (Teplizumab-Mzwv) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC UMR Medical and Drug | FcRn Blockers – Commercial Medical Benefit Drug Policy | 2026-10-01 |
| UHC UMR Medical and Drug | Tzield® (Teplizumab-Mzwv) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | FcRn Blockers – Commercial Medical Benefit Drug Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Tzield® (Teplizumab-Mzwv) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC Surest Medical and Drug | Itvisma® (Onasemnogene Abeparvovec-Brve) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |